Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
bởiAudrey Abella
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
31 Jul 2023
In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.
